Navigation Links
Kendle Announces Details Regarding Fourth Quarter and Full-Year 2010 Earnings Conference Call and Webcast
Date:2/25/2011

CINCINNATI, Feb. 25, 2011 /PRNewswire/ -- Kendle (Nasdaq: KNDL) announced today it will release its fourth quarter and full-year 2010 financial results after the market closes on Wednesday, March 2, 2011. The Company will host a telephone conference call and simultaneous webcast on Thursday, March 3, 2011 at 1:00 p.m. Eastern Time. A question and answer session will follow.

Conference Call Instructions

To participate in the telephone conference call, interested parties in the United States and Canada should dial (800) 946-0716. Participants outside North America should dial (719) 457-2632. All participants should enter conference ID number 5419062. A replay will be available through 5 p.m. Eastern Time on April 4, 2011, by dialing (888) 203-1112 in North America or 719-457-0820 outside of North America and entering conference ID number 5419062.

Webcast Instructions

To access the live webcast, visit

http://ir.kendle.com/phoenix.zhtml?p=irol-eventDetails&c=88712&eventID=3716940.

Instructions for accessing the webcast are provided at the site. The webcast will be archived at www.kendle.com (click on "For Investors" and then "Events & Presentations") shortly after the call for on-demand replay through 5 p.m. Eastern Time on April 4, 2011. Please note that webcast participants will not be able to ask questions.

System requirements for the webcast include Windows Media Player software and at least a 28.8 Kbps connection to the Internet. Media Player is downloadable at no charge from http://www.microsoft.com/windows/windowsmedia/default.aspx.

About Kendle

Kendle International Inc. (Nasdaq: KNDL) is a leading global clinical research organization providing the full range of early- to late-stage clinical development services for the world's biopharmaceutical industry. Our focus is on innovative solutions that reduce cycle times for our customers and accelerate the delivery of life-enhancing products to market for the benefit of patients worldwide. As one of the world's largest global providers of Phase I-IV services, we offer experience spanning more than 100 countries, along with industry-leading patient access and retention capabilities and broad therapeutic expertise, to meet our customers' clinical development challenges.

Additional information and investor kits are available upon request from Kendle, 441 Vine Street, Suite 500, Cincinnati, OH 45202 or from the Company's website at www.kendle.com.


'/>"/>
SOURCE Kendle International Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Kendle to Present at the UBS Global Life Sciences Conference
2. Kendle Named to FORTUNE List of 100 Fastest-Growing Companies for 2008
3. Kendle Reports Record 3Q 08 Net Income and Total Business Authorizations
4. Kendle Named a Best Place to Work in Greater Cincinnati
5. Kendle Reappoints Former CFO Timothy M. Mooney to Board of Directors
6. Kendle to Present at the 2008 Credit Suisse Health Care Conference
7. Kendle to Present at the 2008 Raymond James Boston Fall Investors Conference
8. Kendle Announces Details Regarding Fourth Quarter and Full-Year 2008 Earnings and 2009 Guidance Release, Webcast and Conference Call
9. Kendle to Present at Upcoming Barclays Capital and Raymond James Conferences
10. Kendle Senior Scientist Edward Sellers, MD, PhD, Named One of Nine Notable People in R&D
11. Kendle to Host Conference Call to Discuss Revised 2009 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/27/2016)...  Liquid Biotech USA , ... Sponsored Research Agreement with The University of Pennsylvania ... cancer patients.  The funding will be used to ... clinical outcomes in cancer patients undergoing a variety ... employed to support the design of a therapeutic, ...
(Date:6/24/2016)... , June 24, 2016 Epic ... sensitively detects cancers susceptible to PARP inhibitors by ... tumor cells (CTCs). The new test has already ... therapeutics in multiple cancer types. Over ... DNA damage response pathways, including PARP, ATM, ATR, ...
(Date:6/23/2016)... WA (PRWEB) , ... June 23, 2016 , ... ... announces the release of its second eBook, “Clinical Trials Patient Recruitment and Retention ... recruitment and retention in this eBook by providing practical tips, tools, and strategies ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
Breaking Biology Technology:
(Date:5/20/2016)...  VoiceIt is excited to announce its new ... By working together, VoiceIt and VoicePass will offer ... take slightly different approaches to voice biometrics, collaboration ... usability. Both ... "This marketing and technology partnership allows ...
(Date:5/3/2016)...  Neurotechnology, a provider of high-precision biometric identification ... Identification System (ABIS) , a complete system for ... can process multiple complex biometric transactions with high ... face or iris biometrics. It leverages the core ... MegaMatcher Accelerator , which have been used in ...
(Date:4/26/2016)... , April 27, 2016 ... "Global Multi-modal Biometrics Market 2016-2020"  report to their ... , The analysts forecast the global ... of 15.49% during the period 2016-2020.  ... of sectors such as the healthcare, BFSI, transportation, ...
Breaking Biology News(10 mins):